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Distinct HLA associations of LGI1 and
CASPR2-antibody diseases
Sophie Binks,1,* James Varley,1,* Wanseon Lee,2,* Mateusz Makuch,1 Katherine Elliott,2
Jeffrey M. Gelfand,3 Saiju Jacob,4 M. Isabel Leite,1 Paul Maddison,5 Mian Chen,6
Michael D. Geschwind,3 Eleanor Grant,1 Arjune Sen,1 Patrick Waters,1 Mark McCormack,7
Gianpiero L. Cavalleri,7 Martin Barnardo,6 Julian C. Knight2,* and Sarosh R. Irani1,*
*These authors contributed equally to this work.
The recent biochemical distinction between antibodies against leucine-rich, glioma-inactivated-1 (LGI1), contactin-associated pro-
tein-2 (CASPR2) and intracellular epitopes of voltage-gated potassium-channels (VGKCs) demands aetiological explanations. Given
established associations between human leucocyte antigen (HLA) alleles and adverse drug reactions, and our clinical observation of
frequent adverse drugs reactions in patients with LGI1 antibodies, we compared HLA alleles between healthy controls (n = 5553)
and 111 Caucasian patients with VGKC-complex autoantibodies. In patients with LGI1 antibodies (n = 68), HLA-DRB1*07:01
was strongly represented [odds ratio = 27.6 (95% confidence interval 12.9–72.2), P = 4.1  1026]. In contrast, patients with
CASPR2 antibodies (n = 31) showed over-representation of HLA-DRB1*11:01 [odds ratio = 9.4 (95% confidence interval 4.6–
19.3), P = 5.7  106]. Other allelic associations for patients with LGI1 antibodies reflected linkage, and significant haplotypic
associations included HLA-DRB1*07:01-DQA1*02:01-DQB1*02:02, by comparison to DRB1*11:01-DQA1*05:01-DQB1*03:01
in CASPR2-antibody patients. Conditional analysis in LGI1-antibody patients resolved further independent class I and II associ-
ations. By comparison, patients with both LGI1 and CASPR2 antibodies (n = 3) carried yet another complement of HLA variants,
and patients with intracellular VGKC antibodies (n = 9) lacked significant HLA associations. Within LGI1- or CASPR2-antibody
patients, HLA associations did not correlate with clinical features. In silico predictions identified unique CASPR2- and LGI1-
derived peptides potentially presented by the respective over-represented HLA molecules. These highly significant HLA associations
dichotomize the underlying immunology in patients with LGI1 or CASPR2 antibodies, and inform T cell specificities and cellular
interactions at disease initiation.
1 Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Level 3, West
Wing, John Radcliffe Hospital, Oxford, OX3 9DS, UK
2 Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK
3 UCSF Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, USA
4 Centre for Rare Diseases and Queen Elizabeth Neuroscience Centre, University Hospitals Birmingham, UK
5 Department of Neurology, Queen’s Medical Centre, Derby Road, Nottingham NG7 2UH, UK
6 Transplant Immunology and Immunogenetics Laboratory, Oxford Transplant Centre, Churchill Hospital, Oxford, UK
7 Department of Molecular and Cellular Therapeutics, the Royal College of Surgeons in Ireland, Dublin, Ireland
Correspondence to: Professor Sarosh R. Irani
Oxford Autoimmune Neurology Group
West Wing, Level 3
John Radcliffe Hospital
doi:10.1093/brain/awy109 BRAIN 2018: 141; 2263–2271 | 2263
Received September 8, 2017. Revised January 29, 2018. Accepted February 9, 2018. Advance Access publication May 18, 2018
 The Author(s) (2018). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
Oxford OX3 9DU
UK
E-mail: sarosh.irani@ndcn.ox.ac.uk
Keywords: human leucocyte antigen; leucine-rich glioma-inactivated 1; contactin-associated protein 2; voltage-gated potassium
channel; major histocompatibility complex
Abbreviations: HLA = human leucocyte antigen; VGKC = voltage-gated potassium channel
Introduction
The discovery of autoantibodies against leucine-rich,
glioma-inactivated 1 (LGI1), contactin-associated protein
2 (CASPR2) (Irani et al., 2010; Lai et al., 2010) and,
more recently, intracellular epitopes of voltage-gated potas-
sium channels (VGKCs) (Lang et al., 2017), have redefined
the immunology of the VGKC-complex (Thieben et al.,
2004; Vincent et al., 2004). Patient stratification by these
antigenic targets has shown that the ‘double-negative’
VGKC-complex antibodies, those without LGI1 or
CASPR2 reactivities, are observed across all ages, in
healthy controls and in a variety of syndromes, many of
which are not immune-mediated (Graus and Gorman,
2016; van Sonderen et al., 2016; Lang et al., 2017). In
contrast, patients with LGI1 or CASPR2 antibodies often
have clinically-indistinguishable late-onset forms of limbic
encephalitis and neuromyotonia with associated dysautono-
mia, sleep disturbances, pain and seizures (Irani et al.,
2010; Lai et al., 2010; Klein et al., 2013; Gadoth et al.,
2017). While these features occur at different rates in LGI1-
versus CASPR2-antibody cohorts, only faciobrachial dys-
tonic seizures (FBDS) robustly predict LGI1 reactivity
(Irani et al., 2011; Gadoth et al., 2017; Thompson et al.,
2018). Furthermore, these two autoantibodies are both
often of the IgG4 subclass and frequently co-exist in pa-
tients with the ultra-rare Morvan’s syndrome (Irani et al.,
2012; Arin˜o et al., 2016). The striking overlaps of these
rare neurological features and autoantibodies, and the fre-
quent co-expression of their antigenic targets within mam-
malian CNS-membrane complexes (Irani et al., 2010; Binks
et al., 2018), suggest they are involved in autoimmuniza-
tion. Indeed, this has been reported in abattoir workers
with autoantibodies against VGKC-complexes and, less
so, CASPR2 (Meeusen et al., 2012). The nature of the
available complexes, antigen presentation mechanisms and
the available T cell repertoires are likely to determine which
antigen dominates the ensuing T–B cell response. If so,
human leucocyte antigen (HLA) variants, intimately related
to antigen presentation, may play critical roles in distin-
guishing the aetiology of these syndromes.
Previously, high rates of adverse drug reactions were
observed in patients with LGI1 antibodies, typically second-
ary to antiepileptic drugs (AEDs) and, less so, corticoster-
oids (Irani et al., 2011, 2013; Thompson et al., 2018). As
HLA variants have been implicated in several adverse drug
reactions, including those associated with AEDs and
immunosuppressants (McCormack et al., 2011; Yip et al.,
2015), and have essential antigen-presenting functions
(Trowsdale and Knight, 2013), we hypothesized that
HLA associations existed in patients with LGI1 antibodies.
Indeed, recently, HLA-DRB1*07:01, HLA-DQB1*02:02
and HLA-DRB4 were found to be present in varying pro-
portions of patients with LGI1 antibodies in two cohorts
totalling 40 patients, from Korea and the Netherlands (Kim
et al., 2017; van Sonderen et al., 2017).
To extend these early observations, and given the hy-
pothesis that the VGKC complex may be the initiating
immunizing agent, we sought to compare and contrast
HLA-associations in a sizeable cohort of clinically well-
characterized patients with antibodies against LGI1,
CASPR2, both LGI1 and CASPR2, and VGKCs, and in
silico to identify peptides that may be presented by these
HLA molecules.
Materials and methods
Patients
One hundred and eleven Caucasian patients were identified
from previous studies (n = 51) (Irani et al., 2011, 2013; Lang
et al., 2017), referrals to the Oxford Autoimmune Neurology
Group (n = 46) or from the Autoimmune Encephalopathy
Clinic, University of California San Francisco (n = 14). These
patients had serum antibodies against LGI1 only (n = 68),
CASPR2 only (n = 31), both LGI1 and CASPR2 (n = 3) or
intracellular aspects of VGKCs (n = 9), as determined by pre-
viously described antigen-specific cell-based assays (Irani et al.,
2010; Lang et al., 2017). Clinical phenotypes, including infor-
mation relating to past medical history and adverse drug reac-
tions (Table 1), were evaluated via direct patient and relative
interviews and case-note reviews. All patients provided written
informed consent (REC16/YH/0013 or the IRB 10-04905
approvals).
Genotyping, HLA imputation,
verification and multi-locus
haplotype-block construction
The Infinium Global Screening Array-24 + v1.0 BeadChip with
Illumina Infinium HTS custom markers were used for genotyp-
ing. We proceeded to impute HLA alleles using SNP2HLA
at eight classical loci (HLA-A, HLA-B, HLA-C, HLA-DPA,
HLA-DPB, HLA-DQA1, HLA-DQB1 and HLA-DRB1) at
two-field resolution (Jia et al., 2013; Neville et al., 2017).
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To complement this, DRB1, DRB4 and DQ alleles underwent
intermediate-resolution HLA-typing using PCR-sequence-
specific primers (SSP), updated from Bunce et al. (1995).
PCR-SSP defined the first-field plus a string of second-field
possibilities: the highest frequency allele in Caucasians was
considered most likely. For all discordant data, the PCR-SSP
first-field was accepted as the final result. HLA alleles from
5553 Caucasian healthy controls (from Oxford Biobank)
were available from imputation using the same platforms,
and confirmed in 70 individuals within the same laboratory
by PCR-SSP (Neville et al., 2017). Probable haplotype blocks
were calculated on the basis of a Bayesian algorithm using
PHASE V2 software with 10 000 iterations for three haplotype
blocks: HLA-C-B, HLA-DRB1-DQA1-DQB1, and HLA-
DPA1-DPB1 (Stephens et al., 2001; Stephens and Donnelly,
2003). Further details on genotyping and imputation are pro-
vided in the Supplementary material.
Statistical analyses
For each antibody group, Fisher’s exact test (two-tailed) was
used to compare the HLA allele and haplotype carrier frequen-
cies between patients and the healthy control dataset.
Hochberg’s method was used to correct for multiple compari-
sons. Corrected P-values 5 0.05 were considered significant,
and are presented. Odds ratios (ORs) were calculated using the
median-unbiased estimation method.
Table 1 Clinical features of patients with antibodies to VGKC complex proteins: LGI1, CASPR2, both LGI1 and
CASPR2 or intracellular aspects of VGKCs
LGI1 CASPR2 LGI1 and
CASPR2
VGKC LGI1 versus
CASPR2 (P-value)*
Number of patients 68 31 3 9 ND
Median age at onset age (range) 63 (41–85) 68 (19–82) 56 (52–65) 43 (33–71) ND
Female (%) 20 (29) 2 (6) 1 (33) 4 (44) ND
Clinical syndrome (%)
Epilepsy 8 (12) 2 (6) 0 (0) 4 (44) ND
Encephalitis 58 (85) 18 (58) 1 (33) 2 (22) ND
Morvan’s 1 (2) 3 (10) 2 (67) 0 (0) ND
Isolated neuromyotonia 0 (0) 2 (6) 0 (0) 0 (0) ND
Othera 1 (2) 6 (19) 0 (0) 3 (33) ND
Clinical features (%)
Any seizure 66 (97) 25 (81) 2 (67) 7 (78) 0.01
Faciobrachial dystonic seizures 47 (69) 0 (0) 1 (33) 0 (0) 50.0001
Generalized seizure 26 (38) 10 (32) 2 (67) 6 (67) NS
Amnesia 58 (85) 23 (74) 3 (100) 5 (56) NS
Neuromyotonia 1 (2) 8 (26) 2 (67) 0 (0) 0.0003
Neuropathic pain 5 (7) 14 (45) 2 (67) 0 (0) 50.0001
Autoimmune features (%)
Other autoimmune diseaseb 19 (28) 7 (23) 0 (0) 0 (0) NS
Atopy 8 (12) 2 (6) 2 (67) 1 (11) NS
Adverse effects of corticosteroidsc 32 (47) 5 (16) 0 (0) 1 (11) 0.004
Drug rash 24 (35) 1 (3) 0 (0) 0 (0) 0.0004
Other features
Mean change in mRS (range) 1.6 (3 to 4) 1.5 (0 to 4) 1.7 (0 to 3) 1 (0 to 2) ND
Tumour (%)d 9 (13) 4 (13) 2 (67) 1 (11) ND
Live cell-based assays were used for LGI1 and CASPR2 antibody determination (Irani et al., 2010), and fixed assays to detect antibodies against the intracellular aspects of VGKCs
(Lang et al., 2017).
aOther diagnoses included movement disorders (n = 4, CASPR2, generalized chorea, hemifacial spasm, cervical dystonia and cerebellar ataxia), psychogenic amnesia (n = 2, VGKC
antibodies), widespread non-neuropathic pain (n = 1, VGKC antibodies), axonal neuropathy (n = 1, CASPR2), psychosis (n = 1, CASPR2) and stroke (n = 1 with LGI1 antibodies). Two
patients with antibodies against intracellular VGKC epitopes had epilepsy secondary to structural lesions.
bAutoimmune diseases in LGI1-antibody patients: [n = 19: diabetes (n = 1), heparin-induced thrombocytopaenia (n = 1), hyper- and hypothyroidism and Hashimoto’s thyroiditis
(n = 8), multiple sclerosis (n = 1), myasthenia gravis (n = 1), neuromyelitis optica (n = 1), optic neuritis (n = 1), pernicious anaemia (n = 1), psoriasis (n = 6), Raynaud’s disease (n = 1),
and ulcerative colitis (n = 1)] and CASPR2-antibody patients [n = 7: congenital adrenal hyperplasia, hypothyroidism, pernicious anaemia, pemphigus, polymyalgia rheumatica, psoriasis
and Raynaud’s disease (all n = 1)].
cCorticosteroid-related complications, sometimes multiple, in LGI1-antibody patients [n = 32: marked weight gain (n = 12), behavioural disturbance (n = 5) and diabetes (n = 5), or
worsened diabetes (n = 1), insomnia (n = 4), fracture (n = 3), myopathy or muscle weakness (n = 3), skin thinning/easy bruising (n = 3), mania/hypomania (n = 2), poor wound healing
or abscess (n = 2), ophthalmic infections (n = 2; keratitis and ophthalmic shingles), perforated abdominal viscus (n = 2), and one each of: avascular necrosis of the hip (AVN), cerebral
venous sinus thrombosis, high INR and steroid-induced psychosis] and in CASPR2-antibody patients [n = 5: marked weight gain (n = 1), rash (n = 2), striae/thin skin/bruising (n = 2),
and hallucinations (n = 1)].
dTumours in LGI1-antibody patients (n = 9) were: basal cell carcinoma (n = 3), other skin – type not known (n = 2), bladder (n = 1), breast (n = 1), prostate (n = 1), dysplastic colonic
polyp (n = 1) and in 4 CASPR2-antibody patients were: pancreatic (n = 1), prostate (n = 2), thymic cyst (n = 1).
NS = not significant; ND = not done; mRS = modified Rankin scale (as Thompson et al., 2018).
*Statistical comparisons with Fisher’s exact test throughout.
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HLA binding predictions
The NetMHCIIpan 3.1 server model based on artificial
neural networks (Andreatta et al., 2015) evaluated HLA
haplotype binding affinities for 15-amino acid-long consecu-
tive overlapping peptides from full-length LGI1 and
CASPR2 sequences (UniProt accession numbers O95970
and Q9UHC6, respectively). Predicted peptide affinities
(nM) were compared to 200 000 random peptides of the
same length to generate rank values: this measure is less
susceptible to the intrinsic capacity of some HLA alleles to
generate high-affinity predictions, and rank values (%) 53
were considered strong binders. As expected, consecutive 15-
mer peptides with high rank values often shared a core
sequence.
Results
Clinical differences between patients
stratified by VGKC-complex autoan-
tibody targets
Table 1 summarizes the clinical features of the 111
patients, subgrouped by their autoantibody specificities. In
agreement with previous studies, onset ages were typically
around 60 years, and patients with LGI1 or CASPR2
antibodies most frequently had encephalitis or epilepsy.
FBDS were exclusive to patients with LGI1 antibodies
(P50.0001) who had more seizures (P = 0.01) than
patients with CASPR2 antibodies, where peripheral nerve
features of neuromyotonia (P = 0.0003) and neuropathic
pain (P5 0.0001) were preferentially associated. As
expected, the nine patients with antibodies to intracellular
VGKC epitopes had heterogeneous, often non-immune, clin-
ical syndromes. By contrast, likely non-immune syndromes
were noted in only one patient with LGI1 antibodies
(stroke) and in four with CASPR2 antibodies (axonal neur-
opathy, cervical dystonia, hemifacial spasm and psychosis).
Of greater relevance to a HLA study, patients with LGI1
or CASPR2 antibodies often had co-existent autoimmune
conditions (28% and 23%, respectively), including
Hashimoto’s thyroiditis (n = 8), psoriasis (n = 7) and perni-
cious anaemia (n = 2). Moreover, the LGI1-antibody cohort
was distinctive for a 47% rate of adverse drug reactions
from corticosteroids (P = 0.004; 16% with CASPR2 anti-
bodies) and a significantly higher rate of drug-induced
rashes (35% versus 3% in CASPR2, P = 0.0004). The re-
ported rashes were secondary to AEDs [n = 13: including
carbamazepine (n = 6), phenytoin (n = 4), lamotrigine
(n = 2) and valproate (n = 1)], antibiotics [n = 6: penicillins
(n = 5) and metronidazole (n = 1)] and immunosuppressants
[n = 5: azathioprine (n = 2), corticosteroids (n = 2) and
methotrexate (n = 1)]. Thus, the LGI1- and CASPR2-anti-
body groups displayed differing clinical autoimmune fea-
tures suggesting divergent immunogenetic pathways.
Patients with LGI1 or CASPR2
antibodies have strong and distinct
HLA allelic profiles
We proceeded to analyse HLA associations, as summarized
in Fig. 1 and Table 2. Consistent with previous smaller re-
ports (Kim et al., 2017; van Sonderen et al., 2017), almost all
LGI1-antibody-positive patients carried HLA-DRB1*07:01
(91%, compared to 26% in healthy controls) [OR 27.6
(95% confidence interval, CI 12.9–72.2), P = 4.1  1026].
Further, 13% (9/68) were homozygous for DRB1*07:01,
compared to 2% (115/5553) healthy controls [OR 7.3
(95% CI 3.3–14.4), P = 3  104]. Alleles recognized to be
part of haplotypes involving HLA-DRB1*07:01 (Gonza´lez-
Galarza et al., 2015) were over-represented, namely HLA-
DQA1*02:01, HLA-DQB1*02:02, HLA-DQB1*03:03 and
HLA-DPB1*11:01. Additionally, associations were found
with two HLA class I alleles, HLA-B*57:01 [OR = 3.7
(95% CI 2.0–6.5); P = 0.014] and HLA-C*06:02 [OR = 3.9
(95% CI 2.4–6.3); P = 4.6  105]. After conditioning on the
commonest allele, HLA-DRB1*07:01, two other DQ alleles
reached statistical significance consistent with evidence of an
independent association, HLA-DQA1*01:03 [OR = 4.4
(95% CI 2.2–8.1); P = 4  103] and HLA-DRB1*01:03
[OR = 14.7 (95% CI 3.6–51.5), P = 0.04].
In striking contrast, analysis of the CASPR2-antibody
group identified a single risk allele; HLA-DRB1*11:01,
which was present in 48% of CASPR2-antibody patients
compared to 4% of patients with LGI1 antibodies and 9%
of healthy controls [OR 9.4 (95% CI 4.6–19.3);
P = 5.7  106]. One CASPR2-antibody patient was homo-
zygous for HLA-DRB1*11:01. Interestingly, the four pa-
tients with non-immune conditions and CASPR2
antibodies (Table 1) did not carry HLA-DRB1*11:01,
giving it a 56% (15/27) frequency in the remainder. No
additional alleles were observed after conditioning on
HLA-DRB1*11:01.
Intriguingly, of the three patients with co-existent
CASPR2 and LGI1 antibodies, only one carried HLA-
DRB1*07:01 and none carried HLA-DRB1*11:01.
However, all three carried HLA-B*44:02, HLA-C*05:01,
HLA-DQA1*03:01 and HLA-DQB1*03:01, a different
complement of alleles to the patients with antibodies to
either LGI1 or CASPR2 (Supplementary Fig. 1). There
were no significant findings within the group with intracel-
lular VGKC antibodies (Supplementary Fig. 1).
Haplotype-specific distinctions
between patients with LGI1 and
CASPR2 antibodies
Next, to understand the en bloc allelic inheritance and in vivo
relevance of HLA combinations that may present LGI1 and
CASPR2 antigens, we explored associations involving HLA
haplotypes (Fig. 1B and full analysis in Supplementary Figs
2–4). We noted that HLA-DQA1*02:01, HLA-DQB1*02:02,
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HLA-DQB1*03:03 and HLA-DPB1*11:01 show evidence of
linkage disequilibrium with HLA-DRB1*07:01 (r2 values
0.64, 0.49, 0.13, 0.10 and D0 1, 0.95, 0.8 and 1, respectively)
(Supplementary material). This was reflected in the most fre-
quent HLA class II haplotypes found in patients with LGI1
antibodies, namely HLA-DRB1*07:01-DQA1*02:01-
DQB1*02:02 [OR = 5.2 (95% CI 3.2–8.6); P = 2.3  109],
DRB1*07:01-DQA1*02:01-DQB1*03:03 [OR = 3.1 (95%
CI 1.7–5.5); P = 0.02] and DPA1*02:01-DPB1*11:01
[OR = 4.8 (95% CI 2.5–8.5); P = 3.8  104]. In addition,
LGI1-antibody status was associated with a HLA class I
haplotype, HLA-C*06:02-B*57:01 [OR = 3.6 (95% CI 1.9–
6.2); P = 8.8  103]. By contrast, only one HLA class II
haplotype was associated with CASPR2 antibodies:
DRB1*11:01-DQA1*05:01-DQB1*03:01 [OR = 7.4 (95%
CI 3.5–15.2), P = 5.7  105].
Given these significant and distinct allelic and haplotypic
HLA associations, for each serologically-defined group, we
evaluated their value in explaining sub-phenotypes (limbic
encephalitis or epilepsy; peripheral or CNS), long-term out-
comes or adverse drug reactions (Supplementary Table 1),
and found no significant HLA allele or haplotype associ-
ations. However, within LGI1-antibody patients, five of six
patients with antibiotic-induced rashes carried HLA-
B*57:01 known to associate with risk of rash to abacavir
and flucloxacillin (Yip et al., 2015), and four of six patients
with psoriasis harboured the psoriasis risk allele C*06:02
(Arakawa et al., 2015), suggesting the extended haplotypes
may explain these specific co-morbidities. Finally, from the
nine LGI1- and four CASPR2-antibody patients with a
tumour, there were no significant HLA differences com-
pared to non-tumour patients (Supplementary Table 2).
DRB4 analysis
To extend a previous report (van Sonderen et al., 2017),
the HLA-DRB1 paralogue HLA-DRB4 was sequenced and
observed to be absent or a null allele in 61% (19/31) of the
CASPR2-antibody cohort and 44% (4/9) of the intracellu-
lar VGKC-antibody cohort, consistent with the healthy
control frequencies. However, only 16% (11/68) of the
LGI1-antibody cohort showed an absent or null HLA-
DRB4 allele, and these 11 patients all carried HLA-
DRB1*07:01 (Supplementary Table 3).
Predictions of HLA-binding peptides
These robust HLA class II associations strongly implicate
CD4+ T cells in the pathogenesis of both LGI1- and
CASPR2-antibody-associated diseases. To locate potentially
high-affinity peptides that complex with HLA class II het-
erodimers, and may interact with patient T cells, in silico
Figure 1 HLA allele and haplotype associations in patients with LGI1 and CASPR2 antibodies. Bar chart depicting allele (A) and
haplotype (B) associations and their frequency in patients with antibodies to LGI1 (n = 68, red denotes significant associations) and CASPR2
(n = 31, blue denotes significant associations), together with the frequency of these alleles or haplotypes in 5553 healthy controls (black bars).
HC = healthy controls.
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modelling was used and focused on all the class II haplo-
types identified above (Fig. 2).
Overall, many peptides from both LGI1 and CASPR2
ranked highly for potential binding to several HLA-DR,
HLA-DP and HLA-DQ variants (Fig. 2A and C), likely
consistent with the varied intrinsic properties of different
HLA molecules. Furthermore, for HLA-DRB1*07:01 and
HLA-DRB1*11:01, which pair with the invariant DRA
chain, and for HLA-DQA1*02:01-DQB1*02:02 heterodi-
mers, peptide ranks showed little difference between
LGI1- and CASPR2-derived peptides, suggesting a lack of
antigen selectivity. Also, no highly-ranked peptides were
identified to bind the LGI1-antibody-associated heterodimer
HLA-DQA1*02:01-DQB1*03:03, making it an unlikely
candidate molecule for LGI1 peptide presentation. By con-
trast, the CASPR2-antibody-associated HLA-DQA1*05:01-
DQB1*03:01 heterodimer was predicted to bind some
high-ranking peptides from the CASPR2 sequence only,
suggesting CASPR2 specificity.
As expected for the shared core sequences between con-
secutive 15-mers, many highly ranked peptides were from
tightly clustered locations within the full-length protein
(Fig. 2B, D and Supplementary Table 4). Most peptides
within these clusters showed potential to bind the HLA
variants observed in both the LGI1- and CASPR2-antibody
cohorts (Fig. 2B and D, black circles). This included one
previously identified peptide (Kim et al., 2017) and argues
against its role in disease specificity. However, 9/13 LGI1-
derived peptides and 7/13 from the CASPR2 sequence
showed binding potential that was more restricted to the
variants associated with the corresponding antibody cohort
(Fig. 2B and D, pink circles). From LGI1, 4/9 core peptides
were predicted to bind with high affinity (540 nM), typic-
ally to HLA-DRB1*07:01, although interestingly the high-
est affinity peptide was predicted to bind HLA-
DPA1*02:01-DPB1*11:01 (Supplementary Table 4). From
CASPR2-derived peptides, 7/7 were predicted to bind with
high affinity, distributed across the variants within the
Figure 2 Peptides derived from full-length LGI1 and CASPR2 predicted to bind MHC-dimers encoded by over-represented
HLA haplotypes. Rankings and position of peptides derived from full-length sequences of LGI1 (A and B) and CASPR2 (C and D). The
haplotypes correspond to Fig. 1B and when in bold they relate to those observed in patients with antibodies to the corresponding protein. Red
circles denote the LGI1-antibody cohort and blue the CASPR2-antibody cohort. Grey circles and italicized haplotypes relate to peptides from the
other antigenic protein (i.e. CASPR2 in A and B; and LGI1 in C and D). Rank describes the predicted peptide affinities (IC50, nM) by comparison
to 200 000 random peptides of the same length. Dotted lines represent the 3% cut-off for peptide rank. Within B and D, circles represent the
highly-ranked peptides across the full-length sequences of LGI1 or CASPR2: black circles represent peptides with some predicted promiscuity
across LGI1- and CASPR2-antibody HLA variants, whereas pink circles highlight peptides that are not predicted to cross-react.
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CASPR2-antibody-associated haplotype (Supplementary
Table 4).
Discussion
This study is the first comparative HLA analysis of LGI1-
and CASPR2-autoantibody mediated diseases, and shows
marked and strikingly different HLA associations for
these patients, at both allelic and haplotypic levels. Given
the frequently overlapping clinical features in patients with
LGI1 and CASPR2 antibodies, and their co-expression in
VGKC complexes, these findings indicate that dichotomous
predisposing HLA variants govern the generation of LGI1
versus CASPR2 antibodies. Furthermore, they strongly im-
plicate T cells in disease initiation and the candidate HLA-
binding peptide partners generated by our in silico data
may help identify these interacting T cells.
While HLA-DRB1*07:01 and linked class II alleles,
including the haplotype HLA-DRB1*07:01-DQA1*02:01-
DQB1*02:02, showed very strong associations with
LGI1-antibody patients, this was not observed among
CASPR2-antibody patients in whom we found clear asso-
ciations with HLA-DRB1*11:01 only. Among LGI1-anti-
body patients, DRB1*11:01 was observed at around
healthy control rates, DRB4 was less frequently detected
than DRB1*07:01, homozygosity for HLA-DRB1*07:01
was recognized, and other independent associations
involved HLA class I alleles HLA-B*57:01 and HLA-
C*06:02. Albeit limited by their intrinsic rarity, intri-
guingly, the three patients with both LGI1 and CASPR2
antibodies had yet another complement of HLA alleles.
Perhaps this implicates further divergence in molecular
mechanisms responsible for the generation of both auto-
antibody specificities within an individual. However, the
HLA associations do not appear to distinguish between
sub-phenotypes, outcomes or, in contrast to a previous ob-
servation, the presence of associated tumours (van
Sonderen et al., 2017). Also, the 9–27% frequencies of
these HLA variants in healthy Caucasians are far higher
than disease prevalence, implicating additional loci, envir-
onmental or stochastic influences in disease manifestation.
Furthermore, our data also provide several intriguing in-
sights into the immunopathogenesis of these diseases. First,
they extend the frequent HLA associations in IgG4-related
diseases (Huijbers et al., 2015), but here, exceptionally,
with no DQ5 association. Second, the presence of domin-
ant HLA class II associations implicates extracellular anti-
gen processing and CD4 T cells in disease initiation
(Trowsdale and Knight, 2013), but the LGI1 antibody
class I associations found here, and HLA-B*44:03 and
HLA-C*07:06 reported in seven patients previously (Kim
et al., 2017), are compatible with a role for intracellular
antigen processing, including viruses and drugs. These class
I differences between studies may be explained by ethnicity,
sample size and relatively weak associations (Kim et al.,
2017; van Sonderen et al., 2017). Indeed, this extended
haplotype and the related complex linkage disequilibrium
in this region of the genome warrant further analysis.
Furthermore, our original hypothesis of adverse drug reac-
tion-related HLA variants may relate to the linked adverse
drug reaction-related class I and II HLA variants (HLA-
DRB1*07:01, HLA-DQA1*02:01, HLA-B*57:01) (Yip
et al., 2015). These and future observations in patients
with LGI1 antibodies may inform the genetic basis of
more common adverse drug reactions. Third, the HLA
similarities between tumour and non-tumour LGI1-anti-
body cases suggests the absence of a unique paraneoplastic
signature, in contrast to Lambert-Eaton myasthenic syn-
drome (Wirtz et al., 2005). Perhaps this implies tumours
in patients with LGI1 antibodies largely reflect the age-
matched background rate, rather than a distinct immune
Table 2 Significant allele (top) and haplotype (bottom) associations in patients with LGI1 (n = 68) or CASPR2 (n = 31)
antibodies
Antibody
group
Allele / haplotype OR 95%
CI lower
95%
CI upper
Fisher’s
exact test
Corrected
(Hochberg) P-value
LGI1 B*57:01 3.7 2.0 6.5 5.2  105 1.0  102
LGI1 C*06:02 3.9 2.4 6.3 1.6  107 4.6  105
LGI1 DPB1*11:01 4.9 2.6 8.7 8.4  106 2.0  103
LGI1 DQA1*02:01 8.9 5.2 16.1 3.0  1017 8.7  1015
LGI1 DQB1*02:02 8.1 4.9 13.7 9.5  1017 2.8  1014
LGI1 DQB1*03:03 4.7 2.8 7.7 3.6  108 1.0  105
LGI1 DRB1*07:01 27.6 12.9 72.2 1.4  1028 4.1  1026
CASPR2 DRB1*11:01 9.4 4.6 19.3 2.0  108 5.7  106
LGI1 DRB1*07:01-DQA1*02:01-DQB1*02:02 5.2 3.2 8.6 4.7  1011 2.3  109
LGI1 DRB1*07:01-DQA1*02:01-DQB1*03:03 3.1 1.7 5.5 4.4  104 2.1  102
LGI1 DPA1*02:01-DPB1*11:01 4.8 2.5 8.5 1.0  105 3.8  104
LGI1 C*06:02-B*57:01 3.6 1.9 6.2 1.3  104 8.8  103
CASPR2 DRB1*11:01-DQA1*05:01-DQB1*03:01 7.4 3.5 15.2 1.1  106 5.7  105
Corrected P-values indicate comparison between disease and healthy controls.
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mechanism, although a paucity of tumours classically asso-
ciated with paraneoplastic neurological syndromes may
limit our interpretation. Finally, our in silico predictions
suggest that HLA-DQA1*02:01-DQB1*03:03 is unlikely
to mediate presentation of LGI1-derived peptides, whereas
the HLA-DQA1*05:01-DQB1*03:01 heterodimer may be
implicated in the CASPR2-antibody phenotype. Also, the
promiscuity of both CASPR2 and LGI1 peptides for some
HLA variants, including HLA-DRB1*07:01 (Kim et al.,
2017), may explain why immunization with the same
VGKC complexes may generate two distinct disease enti-
ties, and underlie the observed co-existence of both antibo-
dies at rates far higher than expected by chance (Irani et al.,
2012). However, this in silico approach is inherently lim-
ited by the possibility that high affinity peptides are more
effectively deleted through central tolerance. Nevertheless,
taken together, the range of antigen-restricted peptides
derived herein, and the relative HLA variant frequencies
in disease versus control populations, generate hypothesis-
driven approaches to expand disease-specific T cells in vitro
and complement recent clinical and laboratory observations
which strongly implicate T cell dependence of antibody-
mediated diseases (Makuch et al., 2018; Wilson et al.,
2018a, b).
In summary, the distinct HLA associations in patients
with LGI1 and CASPR2 autoantibodies, together with dif-
fering clinical features relating to autoimmunity, support an
immunological dissociation in generation of these clinically-
overlapping autoantibody-mediated syndromes. The dom-
inant class II HLA involvement combined with in silico
predictions, offers potential to better understand the likely
initiating T–B cell interactions. Further work should focus
on the environmental factors that influence the presentation
of peptides in genetically predisposed individuals.
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